BioNTech SE
BNTX
Cena:
$ 92.14
+1.21 (1.33%)
Valuace
70
Růst
0
Zdraví
55
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
BIONTECH ANNOUNCES APPOINTMENT OF KYLIE JIMENEZ TO MANAGEMENT BOARD AS CHIEF PEOPLE OFFICER
28-01-2026
MAINZ, GERMANY, JANUARY 28, 2026 (GLOBE NEWSWIRE) – BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR ...
Více zde
BIONTECH PROVIDES STRATEGIC BUSINESS UPDATE AND OUTLINES 2026 AREAS OF FOCUS AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
12-01-2026
MAINZ, GERMANY, JANUARY 12, 2026 – BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “THE COMPANY”)...
Více zde
UNIVERSITY OF PENNSYLVANIA, BIONTECH, AND OUP LAUNCH $50 MILLION LIFE SCIENCES FUND
09-01-2026
PHILADELPHIA--(BUSINESS WIRE)--THE UNIVERSITY OF PENNSYLVANIA (“PENN”), BIONTECH SE (“BIONTECH...
Více zde
BIONTECH CLOSES ACQUISITION OF CUREVAC N.V. INCLUDING SUBSEQUENT OFFERING PERIOD TO STRENGTHEN ITS UNIQUE POSITION IN THE MRNA FIELD
18-12-2025
MAINZ, GERMANY, DECEMBER 18, 2025 – BIONTECH SE (NASDAQ: BNTX, “BIONTECH”, OR “THE COMPANY...
Více zde
BIONTECH AND BRISTOL MYERS SQUIBB PRESENT FIRST GLOBAL PHASE 2 DATA FOR PD-L1XVEGF-A BISPECIFIC ANTIBODY PUMITAMIG SHOWING ENCOURAGING EFFICACY IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER
09-12-2025
GLOBAL INTERIM PHASE 2 DATA IN LOCALLY ADVANCED/METASTATIC TRIPLE-NEGATIVE BREAST CANCER (”TNBC”...
Více zde
BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER
06-12-2025
GOTISTOBART DEMONSTRATED A CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT COMPARED TO STANDARD CHEMO...
Více zde
BIONTECH ACHIEVES MINIMUM CONDITION IN CUREVAC EXCHANGE OFFER
03-12-2025
THE MINIMUM CONDITION FOR THE OFFER HAS BEEN SATISFIED, WITH 184,071,410 SHARES OF CUREVAC, REPRESEN...
Více zde
BIONTECH SHARES PROGRESS ON EXCHANGE OFFER FOR CUREVAC SHARES AND HIGHLIGHTS DECEMBER 3, 2025, AT 9:00 A.M. EASTERN TIME EXPIRATION
26-11-2025
MAINZ, GERMANY, NOVEMBER 26, 2025 – BIONTECH SE (NASDAQ: BNTX, “BIONTECH”) TODAY ANNOUNCED THE...
Více zde
BIONTECH ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE
03-11-2025
CONTINUED CLINICAL EXECUTION OF ONCOLOGY STRATEGY WITH FOCUS ON TWO PAN-TUMOR PROGRAMS, INCLUDING CO...
Více zde
BIONTECH TO HOST INNOVATION SERIES R&D DAY ON NOVEMBER 11, 2025
28-10-2025
MAINZ, GERMANY, OCTOBER 28 , 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR ...
Více zde
BIONTECH TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE ON NOVEMBER 3, 2025
27-10-2025
MAINZ, GERMANY, OCTOBER 27, 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR ...
Více zde
BIONTECH COMMENCES PUBLIC EXCHANGE OFFER FOR ALL OUTSTANDING SHARES OF CUREVAC N.V.
22-10-2025
MAINZ, GERMANY, OCTOBER 22, 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH”) T...
Více zde
BIONTECH TO HOST SECOND AI DAY AS AN EDITION OF ITS INNOVATION SERIES ON OCTOBER 1, 2025
23-09-2025
MAINZ, GERMANY, SEPTEMBER 23, 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH”), ...
Více zde
FIRST DISCLOSURE OF GLOBAL INTERIM PHASE 2 DATA FOR BIONTECH AND BRISTOL MYERS SQUIBB PD-L1XVEGF-A BISPECIFIC ANTIBODY PUMITAMIG (BNT327/BMS986545) IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER SHOWS ENCOURAGING ANTITUMOR ACTIVITY
08-09-2025
MAINZ, GERMANY, AND PRINCETON, USA, SEPTEMBER 8, 2025 – BIONTECH SE (NASDAQ: BNTX, “BIONTECH”)...
Více zde
PFIZER AND BIONTECH ANNOUNCE TOPLINE DATA DEMONSTRATING ROBUST IMMUNE RESPONSE WITH THEIR LP.8.1-ADAPTED COVID-19 VACCINE 2025-2026 FORMULA
08-09-2025
NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE, “PFIZER”) AND BIONTECH SE (N...
Více zde
PFIZER AND BIONTECH'S COMIRNATY® RECEIVES U.S. FDA APPROVAL FOR ADULTS 65 AND OLDER AND INDIVIDUALS AGES 5 THROUGH 64 AT INCREASED RISK FOR SEVERE COVID-19
27-08-2025
NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE, “PFIZER”) AND BIONTECH SE (N...
Více zde
BIONTECH ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE
04-08-2025
CONTINUED EXECUTION OF BIONTECH'S ONCOLOGY STRATEGY WITH FOCUS ON TWO PAN-TUMOR PROGRAMS INCLUDING T...
Více zde
PFIZER AND BIONTECH RECEIVE POSITIVE CHMP OPINION FOR LP.8.1-ADAPTED COVID-19 VACCINE IN THE EUROPEAN UNION
25-07-2025
NEW YORK AND MAINZ, GERMANY, JULY 25, 2025 — PFIZER INC. (NYSE: PFE, “PFIZER”) AND BIONTECH SE...
Více zde
8MM EXANTHEMA MARKET REPORT 2025-2034 | RISING VIRAL INFECTIONS AND DIAGNOSTIC INNOVATIONS ACROSS MAJOR MARKETS FUELING GROWTH
23-07-2025
THE EXANTHEMA MARKET IS PROJECTED TO GROW FROM USD 1.39 BILLION IN 2024 TO USD 2.51 BILLION BY 2034 ...
Více zde
BIONTECH TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE ON AUGUST 4, 2025
21-07-2025
MAINZ, GERMANY, JULY 21, 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “T...
Více zde
BIONTECH ANNOUNCES RYAN RICHARDSON TO STEP DOWN FROM THE MANAGEMENT BOARD
17-07-2025
MAINZ, GERMANY, JULY 17, 2025 (GLOBE NEWSWIRE) – BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “T...
Více zde
BIONTECH ANNOUNCES STRATEGIC TRANSACTION TO ACQUIRE CUREVAC IN PUBLIC EXCHANGE OFFER
12-06-2025
MAINZ AND TÜBINGEN, GERMANY, JUNE 12, 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIO...
Více zde
BIONTECH AND BRISTOL MYERS SQUIBB ANNOUNCE GLOBAL STRATEGIC PARTNERSHIP TO CO-DEVELOP AND CO-COMMERCIALIZE NEXT-GENERATION BISPECIFIC ANTIBODY CANDIDATE BNT327 BROADLY FOR MULTIPLE SOLID TUMOR TYPES
02-06-2025
MAINZ, GERMANY, AND PRINCETON, USA, JUNE 2, 2025 -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH”) AN...
Více zde
BIONTECH TO PRESENT PROGRESS ACROSS DIVERSIFIED ONCOLOGY PIPELINE AT THE 2025 ASCO ANNUAL MEETING
27-05-2025
MAINZ, GERMANY, MAY 27, 2025 -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “THE COMPANY”) W...
Více zde
BIONTECH ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE
05-05-2025
CONTINUED ONCOLOGY PIPELINE ADVANCEMENT WITH A STRATEGIC FOCUS ON TWO PRIORITY PAN-TUMOR PROGRAMS: N...
Více zde
BIONTECH ANNOUNCES APPOINTMENT OF RAMÓN ZAPATA TO MANAGEMENT BOARD AS CHIEF FINANCIAL OFFICER
05-05-2025
MAINZ, GERMANY, MAY 5, 2025 (GLOBE NEWSWIRE) – BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “THE...
Více zde
BIONTECH TO PRESENT CLINICAL AND PRECLINICAL DATA ACROSS MRNA AND NEXT-GENERATION IMMUNO-ONCOLOGY PRIORITY PROGRAMS AT AACR 2025
24-04-2025
MAINZ, GERMANY, APRIL 24, 2025 -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “THE COMPANY”)...
Více zde
BIONTECH TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE ON MAY 5, 2025
22-04-2025
MAINZ, GERMANY, APRIL 22, 2025 (GLOBE NEWSWIRE) -- BIONTECH SE (NASDAQ: BNTX, “BIONTECH” OR “...
Více zde
REFRACTORY METASTATIC MELANOMA PIPELINE REPORT 2025, WITH FOCUS ON BIONTECH SE, Y-MABS AND THERAPEUTICS SEAGEN
20-03-2025
DUBLIN, MARCH 20, 2025 (GLOBE NEWSWIRE) -- THE "REFRACTORY METASTATIC MELANOMA - PIPELINE INSIGHT, 2...
Více zde
BIONTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CORPORATE UPDATE
10-03-2025
ADVANCED ONCOLOGY PIPELINE INCLUDING MORE THAN 20 ACTIVE PHASE 2 AND PHASE 3 CLINICAL TRIALS WITH A ...
Více zde
Dokumenty nejsou k dispozici
